Drug Therapy in Knee Osteoarthritis (Thai)
Article Sidebar
Main Article Content
Abstract
โรคข้อเสื่อม (osteoarthritis, OA) เป็นโรคข้อที่พบบ่อยที่สุดในผู้สูงอายุ ประมาณการว่าทั่วโลกมีผู้ป่วยโรคข้อเสื่อมมากกว่า 500 ล้านคน และมีแนวโน้มเพิ่มขึ้นอย่างต่อเนื่องตามโครงสร้างประชากรโลกที่กำลังเข้าสู่สังคมผู้สูงวัยโดยสมบูรณ์1 โรคข้อเสื่อมเป็นสาเหตุสำคัญที่ทำให้ผู้ป่วยมีคุณภาพชีวิตลดลง เกิดความพิการและต้องพึ่งพาผู้อื่น มีผลกระทบถึงครอบครัว สังคม และเศรษฐกิจของประเทศ2
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
(ใส่ข้อความเดียวกันกับ ก๊อปปี้ไลน์ก็ได้)ดูตัวอย่างได้ที่หน้าบทความ---บทความนี้ตีพิมพ์เป็นลิขสิทธื์ของใคร...
References
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-1222.
Cross M, Smith E, Hoy D, Nolte S, Ackerman I, Fransen M, et al. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis. 2014;73(7):1323-1330.
Robinson WH, Lepus CM, Wang Q, Raghu H, Mao R, Lindstrom TM, et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. Nat Rev Rheumatol. 2016;12(10):580-592.
Goldring MB, Otero M. Inflammation in osteoarthritis. Curr Opin Rheumatol. 2011;23(5):471-478.
Tanishi N, Yamagiwa H, Hayami T, Mera H, Koga Y, Omori G, et al. Relationship between radiological knee osteoarthritis and biochemical markers of cartilage and bone degradation (urine CTX-II and NTX-I): the Matsudai Knee Osteoarthritis Survey. J Bone Miner Metab 2009; 27(05):605–612.
Hao HQ, Zhang JF, He QQ, Wang Z. Cartilage oligomeric matrix protein, C-terminal cross-linking telopeptide of type II collagen, and matrix metalloproteinase-3 as biomarkers for knee and hip osteoarthritis (OA) diagnosis: a systematic review and meta-analysis. Osteoarthritis Cartilage 2019;27(05):726–736.
Anandacoomarasamy A, Leibman S, Smith G, Caterson I, Giuffre B, Fransen M, et al. Weight loss in obese people has structure-modifying effects on medial but not on lateral knee articular osteoarthritis: a randomized controlled trial. Arthritis Care Res (Hoboken). 2014 Nov. 66(11): 1680-7.
Bannuru RR, Osani MC, Vaysbrot EE, Arden NK, Bennell K, Bierma-Zeinstra SMA, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578–1589.
Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis & rheumatology. 2020;72(2):220–233.
Piccolo CL, Mallio CA, Vaccarino F, et al. Imaging of knee osteoarthritis: a review of multimodal diagnostic approach. Quant Imaging Med Surg. 2024;14:1022-1041.
Leopoldino AO, Machado GC, Ferreira PH, Pinheiro MB, Day R, McLachlan AJ, et al. Paracetamol versus placebo for knee and hip osteoarthritis. Cochrane Database Syst Rev. 2019;2(2):CD013273.
Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010;18(4):476-499.
Kan HS, Chan PK, Chiu KY, Kan HS, Yan CH, Chiu KY, et al. Non-surgical treatment of knee osteoarthritis. Hong Kong Med J 2019;25(02):127–133.
da Costa BR, Reichenbach S, Keller N, Nartey L, Wandel S, Jüni P, et al. Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis. Lancet. 2017;390(10090): e21-e33.
Nissen SE, Yeomans ND, Solomon DH, Lüscher TF, Libby P, Husni ME, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016;375(26):2519-2529.
FDA Drug Safety Communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. July 9, 2015.
Salis Z, Sainsbury A. Association of long‑term use of non‑steroidal anti‑inflammatory drugs with knee osteoarthritis: a prospective multi‑cohort study over 4‑to‑5 years. Scientific Reports 2024; 14:6593.
Zeng C, Wei J, Persson MSM, Sarmanova A, Doherty M, Xie D1, et al. Relative efficacy and safety of topical non-steroidal anti-inflammatory drugs for osteoarthritis: a systematic review and network meta-analysis of randomised controlled trials and observational studies. Br J Sports Med. 2018;52(10):642-650.
Fuggle N, Curtis E, Shaw S, Fuggle N, Curtis E, Shaw S, et al. Safety of Opioids in Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019;36(Suppl 1):129-143.
da Costa BR, Nüesch E, Kasteler R, Husni E, Welch V, Rutjes AW, et al. Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev. 2014;(9):CD003115.
Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. JAMA. 2016;315(15):1624-1645.
Pergolizzi JV Jr, Labhsetwar SA, Puenpatom RA, Joo S, Ben-Joseph RH, Summers KH. Prevalence of exposure to potential CYP450 pharmacokinetic drug-drug interactions among patients with chronic low back pain taking opioids. Pain Pract. 2011;11(3):230-239.
Frakes EP, Risser RC, Ball TD, Hochberg MC, Wohlreich MM. Duloxetine added to oral NSAIDs for treatment of knee pain due to osteoarthritis” results of a randomized, doubleblind, placebo-controlled trial. Curr Med Res Opin 2011, Dec 27(12): 2361-2372.
McAlindon TE, LaValley MP, Harvey WF, Price LL, Driban JB, Zhang M, et al. Effect of Intra-articular Triamcinolone vs Saline on Knee Cartilage Volume and Pain in Patients with Knee Osteoarthritis: A Randomized Clinical Trial. JAMA. 2017;317(19):1967-1975.
Wernecke C, Braun HJ, Dragoo JL. The Effect of Intra-articular Corticosteroids on Articular Cartilage: A Systematic Review. Orthop J Sports Med. 2015;3(5):2325967115581163.
McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014;22(3):363-388.
Bannuru RR, Natov NS, Obadan IE, Price LL, Schmid CH, McAlindon TE. Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Arthritis Rheum. 2009;61(12):1704-1711.
Russu OM, Pop TS, Feier AM, Trâmbitas C, Incze-Bartha Z, Borodi PG, et al. Treatment efficacy with a novel hyaluronic acid-based hydrogel for osteoarthritis of the knee. J Pers Med 2021;11(04):303.
Friniero L, Govoni E & Bacchini P. Intra-articular hyaluronic acid in the treatment of osteoarthritis of the knee: clinical and morphological study. Clinical Experimental Rheumatology 1998; 16: 441-449.
Jones AC, Pattricj M, Doherty S & Doherty M. lntra-articular hyaluronic acid compared to intra-articular triamcinolone hexacetonide in inflammatory knee osteoarthritis. Osteoarthritis and Cartilage 1995; 3: 269-273.
Richette P, Chevalier X, Ea HK, Eymard F, Henrotin Y, Ornetti P, et al. Hyaluronan for knee osteoarthritis: an updated meta-analysis of trials with low risk of bias. RMD Open. 2015;1(1):e000071.
Carrabba M, Paresce E. Angelini M & Perbellini A. The safety and efficacy of different dose schedules of hyaluronic acid in the treatment of painful osteoarthritis of the knee with joint effusion. European Journal of Rheumatology and Inflammation 1995; 15: 25-31.
Bansal H, Leon J, Pont JL, Wilson DA, Bansal A, Agarwal D, et al. Platelet-rich plasma (PRP) in osteoarthritis (OA) knee: Correct dose critical for long term clinical efficacy. Sci Rep. 2021; 11(1): 3971.
Saita Y, Kobayashi Y, Nishio H, Wakayama T, Fukusato S, Uchino S, et al. Predictors of effectiveness of platelet-rich plasma therapy for knee osteoarthritis: A retrospective cohort study. J Clin Med 2021;10(19):4514.
Knop E, de Paula LE, Fuller R. Plasma rico em plaquetas no tratamento da osteoartrite. Rev Bras Reumatol 2016;56(02): 152–164.
Lana JF, Macedo A, Ingrao ILG, Huber SC, Santos GS, Santana MHA. Leukocyte-rich PRP for knee osteoarthritis: Current concepts. J Clin Orthop Trauma. 2019; 10 (Supp 1): S179-S182.
Shariatzadeh M, Song J, Wilson SL. The efficacy of different sources of mesenchymal stem cells for the treatment of knee osteoarthritis. Cell Tissue Res 2019;378(03):399–410
Spasovski D, Spasovski V, Baščarević Z, Stojiljković M, Vreća M, Anđelković M, et al. Intra-articular injection of autologous adipose-derived mesenchymal stem cells in the treatment of knee osteoarthritis. J Gene Med 2018;20(01): e-3002.
Chen CF, Hu CC, Wu CTE, Wu HT, Chang CS, Hung YP, et al. Treatment of knee osteoarthritis with intra-articular injection of allogeneic adipose-derived stem cells (ADSCs) ELIXCYTE®: a phase I/II, randomized, active-control, single-blind, multiple-center clinical trial. Stem Cell Res Ther 2021;12(01):562.
Arias-Vázquez PI, Tovilla-Zárate CA, Legorreta-Ramírez BG, Fonz WB, Magaña-Ricardez D, González-Castro TB, et al. Prolotherapy for knee osteoarthritis using hypertonic dextrose vs other interventional treatments: systematic review of clinical trials. Adv Rheumatol 2019;59(01):39.
Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et aI. Long-term effects of glucosamine-sulphate on osteoarthricis progression: a randomized, placebo-controlled clinical trial. Lancet 2001;357(9252):251-6.
Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357(9252):251-256.
Uebelhart D, Thonar EJ, Delmas PD, Chantraine A, Vignon E. Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage 1998; 6 Suppl A: 39-46.
Verbruggen G, Goemaere S, Veys EM. Chondroitin sulphate: S/DMOAD (structure/disease modifying anti-osteoarthritis drug) in the treatment of finger joint OA. Osteoarthritis Cartilage 1998; 6 Suppl A: 37-8.
Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006;354(8):795-808.
Marcolongo R, Fioravanti A, Adami S, Tozzi E, Mian M, Zampieri A (1988) Efficacy and tolerability of diacerhein in the treatment of osteoarthritis. Curr Therap Res 43: 878-887.
Maheu E, Mazieres B, Valat JP, Loyau C, Le Loet X, Bourgeois P, et al. Symptomatic efficacy of avocado/soybean unsaponifiables in the treatment of osteoarthritis of the knee and hip: a prospective, randomized, double-blind, placebo-controlled, multicenter clinical trial with a six-month treatment period and a two-month follow-up demonstrating a persistent effect. Arthritis Rheum 1998; 41: 81-91.
Bruyere O, Honvo G, Veronese N, Arden NK, Branco J, Curtis EM, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337–350.
Krishnamurthy A, Lang AE, Pangarkar S, Edison J, Cody J, Sall J. Synopsis of the 2020 US Department of Veterans Affairs/US Department of Defense Clinical Practice Guideline: The Non-Surgical Management of Hip and Knee Osteoarthritis. Mayo Clin Proc. 2021 Sep;96(9):2435-2447.
American Academy of Orthopaedic Surgeons (AAOS) Management of Osteoarthritis of the Knee. Appropriate Use Criteria. https://www.aaos.org/oakauc Published 09/11/2022.49.
Tuure L, Pemmari A, Hämäläinen M, Moilanen T, Moilanen E. Regulation of gene expression by MF63, a selective inhibitor of microsomal PGE synthase 1 (mPGES1) in human osteoarthritic chondrocytes. Br J Pharmacol. 2020 Sep;177(18):4134-4146.
Nakasa T, Ishikawa M, Takada T, Miyaki S, Ochi M. Attenuation of cartilage degeneration by calcitonin gene-related paptide receptor antagonist via inhibition of subchondral bone sclerosis in osteoarthritis mice. J Orthop Res. 2016 Jul;34(7):1177-84.
Hochberg MC, Guermazi A, Guehring H, Aydemir A, Wax S, Fleuranceau-Morel P, et al. Effect of Intra-Articular Sprifermin vs Placebo on Femorotibial Joint Cartilage Thickness in Patients with Osteoarthritis: The FORWARD Randomized Clinical Trial. JAMA. 2019;322(14):1360-1370.
Yazici Y, McAlindon TE, Glbofsky A, Lane NE, Lattermann C, Skrepnik N, et al. A phase 2b randomized trial of lorecivivint, a novel intra-articular CLK/DYRK1A inhibitor and Wnt pathway modulator for knee osteoarthritis. Osteoarthritis Cartilage 2021; 29(5): 654-666.
Yazici Y, Tambiah JRS, Swearingen CJ, Britt J, Kennedy S, Fineman MS, Simsek I, Solomon E, McAlindon TE. A Phase 3, 56-week, randomised, double-blind, placebo-controlled study (OA-11) utilising patient-reported and radiographic outcomes evaluating the efficacy and safety of a lorecivivint injection in patients with moderate to severe knee osteoarthritis. Clin Exp Rheumatol. 2025;43(5):854-60.
Tambiah J, Kennedy S, Swearingen C, McAlindon T, Yazici Y. Impact of structural severity on outcomes in knee osteoarthritis: an analysis of data from phase 2 and phase 3 lorecivivint clinical trials. Rheumatology (Oxford). 2025;64(5):2583-90.
Lauretti GR, Santos DLR, Oliveira CS, Trintade C. The Antinociceptive Effect of Genicular Nerves Block Compared to Intra-Articular Dexamethasone in Grade III or IV Knee Osteoarthritis. J Biomed Sci Eng 2019;12(10):451–457.
Rovati LC, Brambilla N, Blicharski T, Connell J, Vitalini C, Bonazzi A, et al. Efficacy and safety of the first-in-class imidazoline-2 receptor ligand CR4056 in pain from knee osteoarthritis and disease phenotypes: a randomized, double-blind, placebo-controlled phase 2 trial. Osteoarthritis Cartilage. 2020 Jan;28(1):22-30.
Li JW, Wang RL, Xu J, Sun KY, Jiang HM, Sun ZY, et al. Methylene blue prevents osteoarthritis progression and relieves pain in rats via upregulation of Nrf2/PRDX1. Acta Pharmacol Sin. 2022 Feb;43(2):417-428.
Li J, Zhang B, Liu WX, Lu K, Pan H, Wang T, et al. Metformin limits osteoarthritis development and progression through activation of AMPK signalling. Ann Rheum Dis. 2020 May;79(5):635-645.
Lambova SN. Pleiotropic Effects of Metformin in Osteoarthritis. Life 2023, 13, 437.
Guo H, Ding D, Wang L, Yan J, Ma L, Jin Q. Metformin attenuates osteoclast-mediated abnormal subchondral bone remodeling and alleviates osteoarthritis via AMPK/NF-kappaB/ERK signaling pathway. PLoS One. 2021 Dec 16;16(12):e0261127.
Baker MC, Sheth K, Liu Y, Lu D, Lu R, Robinson WH. Development of Osteoarthritis in Adults with Type 2 Diabetes Treated with Metformin vs a Sulfonylurea. JAMA New Open. 2023 Mar 1;6(3):e233646.
Wang Y, Hussain SM, Wluka AE, Lim YZ, Abram F, Pelletier JP, et al. Association between metformin use and disease progression in obese people with knee osteoarthritis: Data from the Osteoarthritis Initiative—A prospective cohort study. Arthritis Res. Ther. 2019, 21, 127.
Song Y, Wu Z, Zhao P. The effects of metformin in the treatment of osteoarthritis: Current perspectives. Front Pharmacol. 2022 Aug 23; 13: 952560.
